×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Yahoo Finance
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary...
1 month ago
Reviewing Atreca (NASDAQ:BCEL) and Aileron Therapeutics (NASDAQ:ALRN)
Defense World
Read Reviewing Atreca (NASDAQ:BCEL) and Aileron Therapeutics (NASDAQ:ALRN) at Defense World.
4 days ago
Aileron reports data from cohort one of Phase Ib inhaled IPF treatment trial
Clinical Trials Arena
Aileron Therapeutics reported positive data from Cohort 1 of a Phase Ib trial of LTI-03 in patients with idiopathic pulmonary fibrosis.
4 weeks ago
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive...
2 weeks ago
Aileron Therapeutics Announces New Interim CFO Appointment - TipRanks.com
Tipranks
An update from Aileron Therapeutics Inc (ALRN) is now available. Aileron Therapeutics, Inc. has appointed Timothy M. Cunningham as the interim chief...
1 week ago
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
Yahoo Finance
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing...
3 weeks ago
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic ...
GlobeNewswire
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological...
4 weeks ago
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under ...
Yahoo Finance
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from...
4 weeks ago
Aileron Therapeutics' Shareholders Approve Major Stock Proposals - TipRanks.com
Tipranks
The latest update is out from Aileron Therapeutics Inc (ALRN). At the 2023 Annual Meeting, shareholders of the company decisively passed several key...
2 months ago
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
Yahoo Finance
Aileron Therapeutics, Inc. (ALRN) has been beaten down lately with too much selling pressure. While the stock has lost 36.3% over the past...
3 weeks ago